Combination therapy with pegylated interferon alpha-2b and adefovir dipivoxil in HBeAg-positive chronic hepatitis B versus interferon alone: a prospective,randomized study

Currently available monotherapies of oral nucleoside/nucleotide analogs or interferon are unable to achieve a sustained and effective response in most of patients with chronic hepatitis B（CHB）. The objective of the present study was to compare the efficacy and safety of pegylated interferon（Peg-IFN） alpha-2b plus adefovir dipivoxil combination therapy versus Peg-IFN alpha-2b alone. Sixty-one HBeAg-positive chronic hepatitis B patients were randomized to receive Peg-IFN alpha-2b alone（1.5 μg/kg once weekly） or Peg-IFN alpha-2b plus adefovir（10 mg daily） for up to 52 weeks. Efficacy and safety analyses were performed on all participants who received at least one dose of study medication. The rate of HBeAg seroconversion and undetectable HBV-DNA were evaluated after 52 weeks of therapy. At the end of treatment, 11 of 30（36.7%） patients receiving combination therapy achieved HBeAg seroconversion versus 8 of 31（25.8%） in the monotherapy group（P=0.36）. In contrast, the percentage of patients with undetectable serum HBV DNA was significantly higher in the combination group than in the monotherapy group（76.7% vs. 29.0%, P〈0.001）. Thyroid dysfunction was more frequent in the combination group than in the monotherapy group（P〈0.05）. In HBeAg-positive CHB, combination of Peg-IFN alpha-2b and adefovir for 52 weeks resulted, at the end of treatment, in a higher virological response but without significant impact on the rate of HBeAg seroconversion and possibly an adverse effect on thyroid function.     

布地奈德福莫特罗粉吸入剂改善支气管哮喘的肺功能临床疗效分析

目的 探讨布地奈德福莫特罗粉吸入剂对支气管哮喘肺功能和临床应用效果的影响.方法 纳入确诊为支气管哮喘的患者50例,随机分为观察组和对照组,每组25例.其中观察组在常规基础治疗的基础上加用布地奈德福莫特罗粉吸入剂,对照组采用常规治疗方法.分别于治疗前及治疗后1个月、3个、6个月观察患者肺功能变化情况,统计患者6 min步行距离、再次入院、支气管哮喘急性发作次数,并对患者生活质量进行评估.结果 2组治疗前及治疗后1个月、3个月肺功能差异无统计学意义(P>0.05);6个月时肺功能观察组优于对照组,差异有统计学意义(P<0.05);观察组前3个月生活质量及6 min步行距离改善情况比较差异无统计学意义(P>0.05);6个月时观察组生活质量及6 min步行距离改善情况优于对照组,差异有统计学意义(P<0.05);治疗后1个月、3个月支气管哮喘急性发作总次数、再次入院次数比较差异无统计学意义(P>0.05),治疗后6个月支气管哮喘急性发作总次数、再次入院次数,对照组明显高于观察组,差异有统计学意义(P<0.05).结论 布地奈德福莫特罗粉吸入剂对支气管哮喘具有良好的治疗效果,一定程度上改善患者的肺功能,提高生活质量.